Skip to main content
. 2022 Nov 28;72(6):1395–1403. doi: 10.1007/s00262-022-03324-z

Fig. 3.

Fig. 3

Subgroup analysis of progression-free survival in HCC after sorafenib failure between TKI group and TKI-ICI group